Citadel Advisors’s BioCardia BCDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-1,147
Closed -$7K 14244
2024
Q1
$7K Sell
1,147
-1,526
-57% -$10.9K ﹤0.01% 13638
2023
Q4
$26.6K Sell
2,673
-54
-2% -$438 ﹤0.01% 12371
2023
Q3
$17.5K Buy
2,727
+994
+57% +$16.7K ﹤0.01% 12725
2023
Q2
$69.4K Sell
1,733
-3,560
-67% -$110K ﹤0.01% 11404
2023
Q1
$156K Buy
5,293
+1,473
+39% +$48.9K ﹤0.01% 10580
2022
Q4
$120K Sell
3,820
-107
-3% -$3.04K ﹤0.01% 10968
2022
Q3
$114K Buy
3,927
+1,187
+43% +$30.7K ﹤0.01% 10976
2022
Q2
$61K Buy
2,740
+1,793
+189% +$42.9K ﹤0.01% 11803
2022
Q1
$29K Sell
947
-4,166
-81% -$124K ﹤0.01% 13118
2021
Q4
$149K Buy
5,113
+3,193
+166% +$117K ﹤0.01% 12263
2021
Q3
$90K Buy
1,920
+1,100
+134% +$53.9K ﹤0.01% 12974
2021
Q2
$49K Buy
+820
New +$49.8K ﹤0.01% 13343

Other funds holding BCDA

Citadel Advisors's BCDA Position: Q1 2026 in Review

Citadel Advisors reduced its BioCardia (BCDA) stake by 33% in Q1 2026, selling an estimated $38.6K and leaving 63,384 shares worth $76.7K. The position accounts for ﹤0.01% of the portfolio, ranked #12204.

Citadel Advisors first reported a position in BCDA in Q4 2020 and has held it in 13 quarters since. The position peaked at $125K in Q2 2021. 18 funds tracked by Wall St. Rank hold BCDA as of Q1 2026.

  • Citadel Advisors held 63,384 shares of BioCardia worth $76.7K as of Q1 2026.
  • Citadel Advisors sold 30,863 BioCardia shares in Q1 2026, an estimated $38.6K.
  • BioCardia made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12204 holding.
  • Citadel Advisors first reported a position in BioCardia in Q4 2020 and has held it in 13 quarters since.
  • Citadel Advisors's BioCardia position peaked at $125K in Q2 2021.
  • 18 funds tracked by Wall St. Rank held BioCardia as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.